<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122810">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02058472</url>
  </required_header>
  <id_info>
    <org_study_id>G3041_BE_I</org_study_id>
    <nct_id>NCT02058472</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic/Pharmacodynamic &amp; Safety Study of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers</brief_title>
  <official_title>An Open Label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety Following Administration of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dong-A Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>South Korea : Korea Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design : randomized, open label, single-dose, 2-way cross-over design

      Phase : Phase I
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUClast, Cmax</measure>
    <time_frame>Blood gathering point : 0h, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 7h, 8h, 12h, 24h, 48h, 72h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax, t1/2, AUCinf, CL/F, Vz/F</measure>
    <time_frame>Blood gathering point : 0h, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 7h, 8h, 12h, 24h, 48h, 72h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ΔAUEC24, ΔEmax, tEmax</measure>
    <time_frame>0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 48h, 72h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Adult Volunteers</condition>
  <arm_group>
    <arm_group_label>G3041</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine orotate 10mg/Olmesartan medoxomil 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEVIKAR®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine besylate 10mg/Olmesartan medoxomil 40mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G3041</intervention_name>
    <arm_group_label>G3041</arm_group_label>
    <arm_group_label>SEVIKAR®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEVIKAR®</intervention_name>
    <arm_group_label>G3041</arm_group_label>
    <arm_group_label>SEVIKAR®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers between the ages of 19 to 55 years old

          -  19 ≤ BMI ≤ 27

          -  having neither congenital/chronic diseases nor pathological symptoms/findings as
             results of medical examination

          -  doctor determines to be suitable as subjects within 4 weeks ago before administration

        Exclusion Criteria:

          -  Hypersensitivity(or history of hypersensitivity) to amlodipine and olmesartan

          -  Exceed 1.5 times of the upper limit of the reference range of AST, ALT, total
             bilirubin, γ-GT

          -  Excessive drinking(exceed alcohol 140g/week)

          -  Excessive caffeine(exceed 4cups/day) and  grape fruit/orange juice(exceed 1cup/day)

          -  Smoking over 10 cigarettes per day
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JW Ko, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 6, 2014</lastchanged_date>
  <firstreceived_date>February 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
